Yearly Archives: 2008

­

Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference

December 1st, 2008|

Presentation to Highlight Results of Ocular Neuroprotection Candidate 
Fremont, CA (December 1, 2008) –   Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its Chief Operating Officer, Dr. Rami Skaliter is scheduled to present results on the Company’s ocular neuroprotection candidate at the 20th Annual Piper Jaffray […]

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

October 13th, 2008|

Quark siRNAs Examined Alone and in Combination with Chemotherapy
Fremont, CA October 13, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the […]

Quark Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property

September 25th, 2008|

Data Validates Neuroprotective Effect of Quark’s New RNAi product on dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma
Fremont, CA September 25, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)- based therapeutics, today announced QPI-1007 as the Company’s first siRNA drug candidate based on its own […]

Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008

September 17th, 2008|

Quark Pharmaceuticals Announces Poster Presentations at RNAI Europe 2008

Fremont, California, September 17, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced the presentation of posters at the 5th Annual RNAi Europe, taking place September 16-18, 2008 in Stockholm, Sweden. Three of Quark’s scientists, Igor Mett, […]

Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME

July 30th, 2008|

Clinical Program Leverages Quark’s RNAi Technology

Fremont, California, July 30, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME). PF-4523655 is a novel […]

Quark Pharmaceuticals Receives FDA Approval of IND For Kidney Transplant siRNA Drug DGFi

June 25th, 2008|

Fremont, California, June 25, 2008 – Quark Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for its siRNA drug candidate, DGFi, in kidney transplantation. The Company expects its Phase I/II clinical study for prevention/treatment of Delayed Graft Function (DGF) in kidney transplant […]

Quark Closes $27 Million Financing

April 7th, 2008|

Funds Will Support Clinical Development of Pipeline Products

Fremont, California, April 7, 2008 – Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, today announced the closing of a private financing totaling an aggregate of $27 million. The major investors are Investment vehicles of SBI Asset Management Co., Ltd. […]